Online first
Wytyczne / stanowisko ekspertów
Opublikowany online: 2024-08-27
Wyświetlenia strony
344
Wyświetlenia/pobrania artykułu
53
Stanowisko ekspertów dotyczące systemowego leczenia okołooperacyjnego chorych na niedrobnokomórkowego raka płuca
Streszczenie
Brak
Referencje
- Endo C, Sakurada A, Notsuda H, et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012; 93(4): 1061–1068.
- Krzakowski M, Jassem J, Antczak A, et al. Thoracic neoplasms. Oncol Clin Pract. 2022; 18(1): 1–39.
- Pignon JP, Tribodet H, Scagliotti GV, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21): 3552–3559.
- Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009; 4(11): 1380–1388.
- Tsuboi M, Herbst R, John T, et al. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. N Engl J Med. 2023; 389(2): 137–147.
- Wu YL, Dziadziuszko R, Ahn JS, et al. ALINA Investigators. Alectinib in Resected -Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14): 1265–1276.
- Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023; 34(10): 907–919.
- Eberhardt WEE, De Ruysscher D, Weder W, et al. Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015; 26(8): 1573–1588.
- De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014; 45(5): 787–798.
- Dunne EG, Fick CN, Jones DR. Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. J Clin Oncol. 2023; 41(22): 3785–3790.
- Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015; 47(6): 545–559.
- Baek J, Owen DH, Merritt RE, et al. Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. Clin Lung Cancer. 2020; 21(4): e265–e269.
- Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019; 158(1): 269–276.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823–1833.
- Brunelli A, Charloux A, Bolliger CT, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34(1): 17–41.
- Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol. 2020; 15(5): 709–740.
- Patomorfologia: standardy i przykłady dobrej praktyki oraz elementy diagnostyki różnicowej. Wytyczne dla zakładów/pracowni patomorfologii. https://pol-pat.pl/index.php/standardy-i-wytyczne-w-patomorfologii/ (22.07.2024).
- Standardy organizacyjne oraz standardy postępowania w patomorfologii. Wytyczne dla zakładów/pracowni patomorfologii. https://pol-pat.pl/index.php/standardy-i-wytyczne-w-patomorfologii/ (22.07.2024).
- Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018; 29(8): 1853–1860.
- Dacic S, Travis W, Redman M, et al. IASLC Pathology Committee. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023; 18(10): 1290–1302.
- William WN, Pataer A, Kalhor N, et al. University of Texas M.D. Anderson Lung Cancer Collaborative Research Group, University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012; 7(5): 825–832.
- Weissferdt A, Leung CH, Lin H, et al. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol. 2024; 37(1): 100353.
- Berezowska S, Keyter M, Bouchaab H, et al. Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy. Adv Anat Pathol. 2024 [Epub ahead of print].
- Deutsch JS, Cimino-Mathews A, Thompson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024; 30(1): 218–228.
- Rami-Porta R. The Evolving Concept of Complete Resection in Lung Cancer Surgery. Cancers (Basel). 2021; 13(11).
- Langfort R, Krzakowski M, Kowalski D, et al. Expert opinion on adjuvant treatment with osimertinib in patients with non-small cell lung carcinoma after radical tumor resection. Oncol Clin Pract. 2023; 19(4): 205–216.
- O'Brien M, Paz-Ares L, Marreaud S, et al. EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10): 1274–1286.
- Forde PM, Spicer J, Lu S, et al. CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21): 1973–1985.
- Cascone T, Awad MM, Spicer JD, et al. CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024; 390(19): 1756–1769.
- Wakelee H, Liberman M, Kato T, et al. KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 389(6): 491–503.
- Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Transl Lung Cancer Res. 2020; 9(4): 1690–1698.
- Lamb BW, Brown KF, Nagpal K, et al. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol. 2011; 18(8): 2116–2125.
- Lazaridis KN, Schahl KA, Cousin MA, et al. Individualized Medicine Clinic Members. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. Mayo Clin Proc. 2016; 91(3): 297–307.
- Mancini GMS, Smits DJ, Dekker J, et al. Multidisciplinary interaction and MCD gene discovery. The perspective of the clinical geneticist. Eur J Paediatr Neurol. 2021; 35: 27–34.
- Bai R, Li W, Du N, et al. Challenges of evaluating immunotherapy efficacy in solid tumors. Chin J Cancer Res. 2019; 31(6): 853–861.
